End Stage Renal Disease Market Size & Growth Forecast 2027–2036, By Segments (Treatment), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
End Stage Renal Disease Market size was estimated at USD 152.29 billion in 2026 and is projected to grow at a 12.35% CAGR from 2027 to 2036, attaining USD 487.98 billion by 2036. The industry revenue for 2027 is assessed at USD 168.13 billion.
Get more details on this report
Request Free Sample ReportEnd Stage Renal Disease Market Intelligence Snapshot
Regional Market Dynamics
- North America leads the market with established dialysis and transplant infrastructure, specialized nephrology services, and organized treatment pathways that sustain consistent demand for renal care.
- Asia Pacific is projected to expand at a 14.34% CAGR as dialysis access improves, renal care capacity increases, and more patients enter formal long-term treatment pathways.
Segment Momentum
- Dialysis accounted for 74.4% of the market in 2026 because it remains the most established and widely accessible long-term renal replacement therapy for patients requiring ongoing disease management.
- Dialysis is also the fastest-growing treatment segment as the expanding patient population continues to require accessible, recurring renal replacement therapy delivered through established care pathways.
Market Expansion Drivers
- Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand.
- Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes.
- Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally.
Leading Market Participants
- Major players in the end stage renal disease market include Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (United States), Nipro Corporation (Japan), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), Becton Dickinson and Company (United States), Asahi Kasei Medical Co., Ltd. (Japan), Nikkiso Co., Ltd. (Japan), JMS Co., Ltd. (Japan), DaVita Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 152.29 billion
- 2027 Estimated Market Size: USD 168.13 billion.
- Projected Market Size: USD 487.98 billion by 2036
- Growth Forecast: 12.35% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Dialysis (Treatment)
- Emerging Opportunity Segment: Dialysis (Treatment)
Market Growth Drivers and Industry Trends
Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand
The growing burden of diabetes and hypertension is contributing to a larger population at risk of progressive kidney damage, creating sustained demand across the end stage renal disease market. Both conditions can impair renal function over time, and patients who progress to advanced kidney failure often require ongoing dialysis, transplantation evaluation, medication management, and specialized renal care. The increasing incidence of these chronic diseases, combined with longer patient lifespans and greater recognition of kidney complications, is expanding the need for long-term treatment pathways and recurring renal care services.
Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes
Advances in dialysis machines, monitoring systems, filtration technologies, and treatment management are improving the ability of healthcare providers to deliver more controlled and patient-focused renal therapy. These innovations are supporting end stage renal disease market growth by enhancing treatment precision, simplifying equipment operation, and enabling closer monitoring of patients during dialysis. Improvements in equipment design and treatment capabilities can also support safer and more convenient care across different clinical settings, while technological integration helps healthcare professionals manage complex treatment requirements and respond more effectively to changes in patient condition.
Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally
Greater acceptance of home-based dialysis is shifting renal treatment toward more decentralized care models and increasing the need for equipment, supplies, training, and support services outside traditional healthcare facilities. Expansion of the end stage renal disease market is supported as suitable patients seek treatment options that offer greater flexibility and reduce dependence on frequent visits to dialysis centers. Home dialysis programs also encourage healthcare systems to develop supporting infrastructure for patient education, remote monitoring, equipment delivery, and clinical follow-up, enabling treatment to be incorporated more conveniently into patients' daily routines.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing prevalence of end-stage renal disease | 4.50% | Short term (≤ 2 yrs) | North America, Europe (spillover: Asia Pacific) | High | Fast |
| Adoption of dialysis and renal care devices | 4.00% | Medium term (2–5 yrs) | Europe, Asia Pacific (spillover: North America) | Medium | Moderate |
| Expansion of renal care centers in emerging markets | 4.30% | Long term (5+ yrs) | North America, Europe (spillover: Asia Pacific) | Medium | Slow |
| Rising prevalence of diabetes and hypertension increasing long-term dialysis and renal care demand | 2.50% | High | North America, Asia Pacific | High | Near Term |
| Technological advancements in dialysis equipment improving treatment accessibility and patient outcomes | 2.10% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Expanding home dialysis adoption strengthening decentralized renal care infrastructure globally | 1.70% | High | North America, Europe | Emerging | Long Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
In the end stage renal disease market, North America held the largest position in 2026, supported by advanced renal care infrastructure, broad access to dialysis services, and established clinical capabilities for managing complex kidney disorders. A substantial burden of chronic conditions associated with kidney failure contributes to sustained demand for renal replacement therapies and supportive care. Strong healthcare systems, specialist expertise, reimbursement mechanisms, and continued adoption of home-based and technologically enabled treatment approaches further strengthen the regional market, while ongoing improvements in patient monitoring and dialysis management support care continuity.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, reflecting expanding healthcare access, increasing awareness of kidney disease, and improvements in renal treatment infrastructure. Rising availability of specialized care facilities and greater investment in healthcare capacity are helping address unmet needs among patients requiring long-term renal replacement therapy. Growing adoption of modern dialysis technologies, wider availability of trained medical professionals, and increasing emphasis on early detection and chronic disease management are contributing to stronger demand for end stage renal disease treatment across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Treatment PathwaysGermany focuses on high-quality dialysis infrastructure and coordinated nephrology care for patients with end stage renal disease. Clinical providers in Germany are adopting advanced monitoring technologies and personalized treatment approaches to improve therapy efficiency and patient outcomes.
France 🇫🇷
Coordinated Patient ManagementFrance prioritizes multidisciplinary renal care supported by structured healthcare networks and standardized treatment pathways. Healthcare providers across France focus on improving patient access, treatment quality, and coordinated monitoring for individuals living with end stage renal disease.
Italy 🇮🇹
Clinical Service ModernizationItaly continues modernizing dialysis facilities and expanding access to specialized nephrology services for end stage renal disease. The Italian healthcare system supports technology adoption and coordinated clinical management to improve treatment efficiency and patient experience.
Japan 🇯🇵
Home Dialysis EvaluationJapan continues refining renal care through efficient dialysis delivery and evaluation of home-based treatment options. Healthcare institutions in Japan emphasize treatment consistency, patient safety, and technology-supported disease management for individuals with end stage renal disease.
South Korea 🇰🇷
Digital Care IntegrationSouth Korea integrates digital health solutions with dialysis services to strengthen long-term management of end stage renal disease. Providers in South Korea are expanding remote monitoring capabilities and optimizing hospital workflows to improve continuity of patient care.
United States 🇺🇸
Advanced Renal CareThe U.S. prioritizes integrated dialysis services, home-based treatment expansion, and improved patient monitoring for end stage renal disease. Healthcare providers in the U.S. continue investing in digital care pathways and innovative renal therapies to enhance long-term patient management.
Segment Leadership and Growth Trends
End Stage Renal Disease Market Share (%), by Treatment, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTreatment Segment Analysis: Dialysis (Largest & Fastest-Growing Segment)
The dialysis segment dominated the end stage renal disease market with a 74.4% share in 2026 and also represents the fastest-growing treatment segment. Its leading position is supported by the essential role of dialysis in managing patients whose kidneys can no longer adequately remove waste, excess fluids, and electrolytes from the bloodstream. Hemodialysis and peritoneal dialysis provide established treatment pathways for patients who require ongoing renal replacement therapy, making dialysis a core component of end stage renal disease management. Growing prevalence of conditions associated with progressive kidney failure, together with continued demand for accessible and reliable renal replacement care, supports sustained utilization. Advances in dialysis equipment, treatment efficiency, patient monitoring, and home-based modalities are further improving treatment flexibility and helping expand access beyond conventional clinical settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Treatment | Transplant, Dialysis | Dialysis | Dialysis |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Prominent players in the end stage renal disease market:
1. Fresenius Medical Care AG & Co. KGaA (Germany)
2. Baxter International Inc. (United States)
3. Nipro Corporation (Japan)
4. Medtronic plc (Ireland)
5. B. Braun Melsungen AG (Germany)
6. Becton Dickinson and Company (United States)
7. Asahi Kasei Medical Co. Ltd. (Japan)
8. Nikkiso Co. Ltd. (Japan)
9. JMS Co. Ltd. (Japan)
10. DaVita Inc. (United States)
Growing demand for patient-centered renal care is transforming the end stage renal disease market, with increasing adoption of home-based therapies, digital health monitoring, and integrated treatment approaches. Technological innovation continues to improve treatment accessibility and long-term disease management.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA (Germany) | |||||||
| Baxter International Inc. (United States) | |||||||
| Nipro Corporation (Japan) | |||||||
| Medtronic plc (Ireland) | |||||||
| B. Braun Melsungen AG (Germany) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Asahi Kasei Medical Co. Ltd. (Japan) | |||||||
| Nikkiso Co. Ltd. (Japan) | |||||||
| JMS Co. Ltd. (Japan) | |||||||
| DaVita Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| SERB Pharma | May-26 | SERB Pharma has acquired the exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union and MENA regions from Hansa Biopharma for €115 million. This acquisition strategically expands access to desensitization therapy for highly sensitized patients awaiting kidney transplants, addressing a critical unmet need in renal care by facilitating transplants for patients with previously limited options. |
| Hansa Biopharma | Sep-25 | Hansa Biopharma announced positive topline results from the U.S. Phase 3 ConfIdeS trial of imlifidase, demonstrating superior kidney function at 12 months in highly sensitized patients. The statistically significant findings validate the efficacy of imlifidase as a desensitization therapy, strengthening the company's regulatory path toward FDA approval and potentially transforming the standard of care for patients with high immunological barriers to transplantation. |
| Renvio | Sep-25 | Renvio partnered with Klinrisk to integrate predictive artificial intelligence into clinical renal care workflows. The platform provides real-time risk assessment for hospitalization and treatment complications directly within existing electronic medical record systems. This digital transformation effort allows dialysis clinics to move from reactive treatment to proactive care management, potentially reducing hospitalizations and improving operational efficiency in ESRD service delivery. |
| Montefiore Einstein | Aug-25 | Montefiore Einstein successfully implemented advanced robotic surgical techniques for kidney transplantation, specifically targeting high-risk and obese ESRD patients. This expansion of surgical capability addresses existing clinical barriers to transplantation, allowing a broader patient population to become eligible for donor organs and signaling a shift in clinical practice toward more minimally invasive and accessible transplant surgery. |
| Centers for Medicare & Medicaid Services (CMS) | May-25 | CMS launched a restructured Kidney Care Choices (KCC) Model to incentivize value-based care and increase adoption of home dialysis and kidney transplantation. By shifting reimbursement strategies, the model aims to improve clinical outcomes and operational efficiency within the nephrology value chain, pressuring providers to optimize patient management and reduce long-term costs associated with conventional in-center hemodialysis. |
| Seoul National University | Apr-25 | Researchers at Seoul National University have developed a compact, portable artificial kidney utilizing advanced peritoneal dialysis technology. This innovation aims to enable broader home-based renal replacement therapy by reducing the logistical and mechanical burdens associated with traditional dialysis equipment, representing a significant step toward improving patient autonomy and quality of life for those with end-stage renal disease. |
| eGenesis | Oct-24 | eGenesis secured $191 million in Series D funding to accelerate the development of genetically engineered, human-compatible porcine kidneys. The investment supports the advancement of its lead candidate, EGEN-2784, toward first-in-human clinical trials. This development represents a significant potential breakthrough in alleviating the global organ shortage, which remains a primary barrier to improved outcomes in end-stage renal disease treatment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
End Stage Renal Disease Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Payer Type | Public Insurance, Private Insurance, Self-Pay |
| Care Setting | In-Center Care, Home-Based Care, Hospital-Based Care |
| Disease Etiology | Diabetes-Related ESRD, Hypertension-Related ESRD, Glomerular & Autoimmune Diseases, Genetic & Congenital Disorders, Other Causes |
End Stage Renal Disease Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Home Dialysis Adoption Assessment |
|
| Value-Based Care Opportunity Assessment |
|
| Renal Therapy Access Gap Analysis |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of end stage renal disease?
What is the forecasted size of the end stage renal disease industry?
How are rising diabetes and hypertension rates impacting dialysis demand in the end stage renal disease market?
How is the shift toward home-based dialysis changing care delivery models in the end stage renal disease market?
Why is dialysis the dominant treatment in the end stage renal disease market?
Which treatment segment is growing fastest in the end stage renal disease market?
Why is North America the largest end stage renal disease market?
What factors are driving end stage renal disease market growth in Asia Pacific?
Which companies dominate the end stage renal disease landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization